← Back to Search

Anticoagulant

Vascular dose for Intermittent Claudication

Phase 4
Waitlist Available
Research Sponsored by Science Valley Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin alone improves on intermittent claudication distance in PAD patients.

Eligible Conditions
  • Intermittent Claudication
  • Peripheral Arterial Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute claudication distance (ACD) on treadmill
Initial claudication distance (ICD) and the total walking distance (TWD) on 6 MWT
Quality of life Walking Impairment Questionnaire (WIQ)
Secondary outcome measures
Major adverse cardiovascular event
Major adverse events of the limbs
Other outcome measures
Bleeding

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Vascular doseExperimental Treatment1 Intervention
Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
Group II: AspirinActive Control1 Intervention
Aspirin 100 mg OD for 6 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylsalicylic acid
FDA approved

Find a Location

Who is running the clinical trial?

Science Valley Research InstituteLead Sponsor
8 Previous Clinical Trials
1,243 Total Patients Enrolled
BayerIndustry Sponsor
2,240 Previous Clinical Trials
25,332,689 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
2021. "Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04853719.
~22 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top